Analytical approaches for antimalarial antibody responses to confirm

² historical and recent malaria transmission in malaria-endemic areas in the

3 Philippines

4 Maria Lourdes M. Macalinao^{1,2,3}, Kimberly M. Fornace^{2,4}, Ralph A. Reyes¹, Alison Paolo N. Bareng¹, Tom

Hall², John H. Adams⁵, Christèle Huon⁶, Chetan E. Chitnis⁶, Jennifer S. Luchavez¹, Kevin K. A. Tetteh²,

6 Katsuyuki Yui^{3,7}, Julius Clemence R. Hafalla², Fe Esperanza J. Espino¹, Chris J. Drakeley^{2*}

¹Department of Parasitology and National Reference Centre for Malaria and Other Parasites, Research Institute 7 for Tropical Medicine, Department of Health, Muntinlupa City, Philippines; ²Faculty of Infectious Tropical Diseases, 8 Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and 9 Tropical Medicine, London, United Kingdom; ³School of Tropical Medicine and Global Health, Nagasaki University, 10 Nagasaki, Japan; ⁴Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, 11 Glasgow, United Kingdom; ⁵University of South Florida, Tampa, FL, 33612, USA; ⁶Malaria Parasite Biology 12 and Vaccines Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France, ⁷Shionogi 13 Global Infectious Diseases Division, Institute of Tropical Medicine, Nagasaki University 14

15 *For correspondence: Chris.Drakeley@lshtm.ac.uk (CJD)

16 Abstract

Assessing the status of malaria transmission in endemic areas becomes increasingly challenging as 17 countries approach elimination and infections become rare. Here, we evaluated the use of multiplex antibody 18 19 response data to malaria-specific antigens to classify recent and historical infections of differentially exposed 20 populations in three provinces in the Philippines. We utilized samples (n=9132) from health-facility based 21 cross-sectional surveys in Palawan (ongoing malaria transmission), Occidental Mindoro (limited transmission), and Bataan (no transmission) and quantified antibody responses against 8 Plasmodium 22 falciparum and 6 P. vivax-specific antigens. Different statistical and machine learning analytical methods 23 were used to examine associations between antigen-specific antibody responses with malaria incidence, 24 and the ability to predict recent or historical exposure. Consistent with the provinces' endemicity status, 25 antibody levels and seroprevalence were consistently highest in Palawan and lowest in Bataan. A machine 26 learning (ML) approach (Random Forest model) using identified responses to 4 antigens (PfGLURP R2, 27 Etramp5.Aq1, GEXP18 and PfMSP1₁₉) gave better predictions for *P. falciparum* infection (positive by 28 microscopy, RDT and/or PCR) or likely recent exposure in Palawan (AUC: 0.9591, CI 0.9497-0.9684) than 29 mixture models calculating seropositivity to individual antigens. Meanwhile, employing the same ML 30 approaches for the vivax-specific antigens did not improve predictions for recent P. vivax infections. Still. 31 the antigen panel was overall able to confirm the absence of recent exposure to P. falciparum and P. vivax 32 in both Occidental Mindoro and Bataan through single and ensemble ML approaches. Seroprevalence and 33 seroconversion rates based on cumulative exposure markers AMA1 and MSP1₁₉ showed accurate trends 34 of historical P. falciparum and P. vivax transmission in the 3 sites. Our study emphasizes the utility of 35 serological markers in predicting recent and historical exposure in a sub-national elimination setting, 36 establishes baseline antibody data for monitoring risk in malaria-endemic areas in the Philippines, and also 37 highlights the potential use of machine learning models using multiplex antibody responses to accurately 38 assess the malaria transmission status of countries aiming for elimination. 39

40

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 Introduction

The Philippines is aiming to eliminate malaria by 2030 following a sub-national elimination approach (World 42 Health Organization, 2014). The country had more than 70% decrease in malaria cases in the past decade, 43 with only 2 provinces reporting local cases; 19 provinces are in elimination phase, and the remaining 60 44 declared malaria-free in 2021. Plasmodium falciparum (Pf) contributes more than 80% to the total malaria 45 cases, P. vivax (Pv) is at >20%, while the other species P. malariae, P. ovale and P. knowlesi make up <1% 46 of the cases (World Health Organization, 2019). As the number of areas still reporting local cases continue 47 to decrease, assessing the malaria levels in endemic areas and differentiating areas with residual 48 transmission becomes increasingly challenging. Innovative tools that are capable of detecting both past and 49 present infections can be used to confirm the presence or absence of malaria transmission in endemic areas 50 supporting sub national specific control approaches (Drakeley et al., 2005; malERA Refresh Consultative 51 Panel, 2017; World Health Organization and Global Malaria Programme, 2017). 52

Several studies have utilized serology and malaria-specific antibody responses to estimate malaria 53 transmission intensities (Folegatti et al., 2017; Fowkes et al., 2010), showing that these represent a viable 54 additional metric of both historical and recent exposure (van den Hoogen et al., 2015; Idris et al., 2017; 55 Kerkhof et al., 2016; Pothin et al., 2016; Ssewanyana et al., 2017; Wu et al., 2020a). Antibody prevalence 56 alone and as age-adjusted seroconversion rates correlate with entomological and parasitological measures 57 used in estimating malaria transmission (Corran et al., 2007; Niass et al., 2017; Stanisic et al., 2015). 58 59 Many of the original studies examined single antigen platforms and antigens associated with cumulative exposure to infection such as Pf apical membrane antigen-1 (PfAMA1) and the 19KDa fragment of Pf 60 merozoite protein 1 (PfMSP1₁₉). More recent advances in array and bead-based assay platforms allow for 61 simultaneous analysis of antibody responses to multiple antigens (Fouda et al., 2006; Kerkhof et al., 2016; 62 Koffi et al., 2015; Ondigo et al., 2012; Perraut et al., 2014; Wu et al., 2019). These approaches increase 63 assay throughput and allow the inclusion of multiple targets that can represent diversity in the parasite and 64 allow for variation in individual immune response. Recent multi-antigen studies have identified markers 65 associated with antibody responses describing recent and historical P. falciparum and P. vivax exposure 66 (Helb et al., 2015; van den Hoogen et al., 2015; Longley et al., 2020; Wu et al., 2020b). To fully realize 67 the additional information provided by examining multiple antigenic targets, these studies have employed 68 more advanced statistical approaches and algorithms such as machine learning to predict optimal 69 combinations of antibody responses for the outcome of interest. 70

The overall aim of this study was to evaluate known malaria-specific P. falciparum and P. vivax serological 71 markers for their predictive capacity to distinguish current or recent infections from historically exposed 72 individuals in order to better describe malaria endemicity in three areas of the Philippines. Specifically, we 73 sought to evaluate different approaches to determining seropositivity for estimating malaria transmission 74 intensities and exposure in areas of varying endemicity. To achieve this, we: 1) measured malaria-specific 75 antibody responses in participants recruited through health facility surveys in 3 sites in the Philippines, 2) 76 evaluated analysis methods to determine seropositivity using single and multiple antigens, and 3) analyzed 77 antibody responses and estimated transmission intensities in relation to the supposed immune status of 78 these populations. Our findings detailing the antibody responses to multiple malaria-specific antigens 79 demonstrate the utility of serology in showing the heterogeneity of malaria transmission in malaria-endemic 80 populations in the Philippine setting. 81

82 Methods

83 Ethical approval

This study was reviewed and approved by the Research Institute for Tropical Medicine – Institutional Review Board (RITM IRB 2016-04) and LSHTM Research Ethics Committee (11597).

86 Study Sites and Samples

The study was conducted in 3 municipalities in 3 87 provinces in the Philippines, representing areas of 88 varying malaria endemicity 1) Rizal in the province 89 of Palawan, which is currently the most endemic 90 area in the Philippines, and reported more than 91 60% of the total cases in the country (annual 92 parasite index (API) of 5.7 per 1,000 risk 93 population) in 2018; 2) Abra de llog, Occidental 94 Mindoro, a municipality reporting sporadic local 95 cases at the time of the survey and with declining 96 transmission (API of 0.38 in 2018); and 3) Morong 97 in Bataan with a last reported indigenous case in 98 2011 and declared malaria-free in 2019 (Figure 99 100 1).

Participants were recruited from June 2016 to 101 June 2018 in a health facility-based rolling cross-102 sectional survey detailed in Reves et al (2021). 103 Briefly, all consulting patients, as well as their 104 companions, were invited to participate and 105 provide a finger-pricked blood sample for malaria 106 diagnosis through microscopy (blood smear), 107 rapid diagnostic test (RDT), and a dried blood spot 108 109 sample on Whatman 3MM CHR filter paper for malaria diagnosis by PCR and serological 110 analysis. The DBS samples were air-dried and 111 stored in resealable bags with desiccant at 4°C 112 while in the field, and transported at ambient 113 temperatures to the laboratory facility, where it 114 was stored at 4°C and -20°C for short- and long-115 term storage, respectively. A total of 9,132 DBS 116 samples (6572 for Palawan, 1683 for Occidental 117



118 Mindoro, and 877 for Bataan) were available for analysis for this study.

119 Multiplex bead-based assay of malaria-specific antibodies

Serological analysis was conducted using a multiplex bead-based assay as previously described (Coutts 120 et al., 2017; Helb et al., 2015; van den Hoogen et al., 2020b), with an antigen panel that included 8 P. 121 falciparum-specific and 6 P. vivax-specific recombinant antigens coupled to Magplex beads (Luminex Corp, 122 Austin, TX, USA). The antigens were PfAMA1 (apical membrane antigen 1), PfMSP119 (merozoite surface 123 protein), and their *P. vivax* homologues PvAMA1 and PvMSP1₁₉; PfGLURP R2 (glutamate rich protein), 124 Etramp5.Ag1 (early transcribed membrane protein 5), PfSEA1 (schizont egress antigen), GEXP18 125 (Gametocyte exported protein 18), MSP2 CH150/9 (CH150/9 allele of MSP2), MSP 2 Dd2 (Dd2 allele of 126 MSP2), PvEBP (erythrocyte binding protein), PvRBP1a (reticulocyte binding protein 1a), PvRII and PvDBPRII 127 (region II, Duffy binding protein). Antigen characteristics are shown in Table 1. 128

129

Antigen	Description	Gene ID	Reference
Pf-specific			
PfAMA1	apical membrane antigen 1	PF3D7_1133400	Collins et al., 2007
PfMSP1 ₁₉	19 kDa fragment of merozoite surface protein (MSP) 1	PF3D7_0930300	Burghaus and Holder, 1994
PfGlurp R2	glutamate rich protein R2	PF3D7_1035300	Theisen et al., 1995
Etramp5.Ag1	early transcribed membrane protein 5	PF3D7_0532100	van den Hoogen et al., 2019; Spielmann et al., 2003
PfSEA1	schizont egress antigen	PF3D7_1021800	Raj et al., 2014
GEXP18	Gametocyte exported protein 18	PF3D7_0402400	Helb et al., 2015
MSP2 CH150	CH150/9 allele of MSP2	PF3D7_0206800	Polley et al., 2006
MSP2 Dd2	Dd2 allele of MSP2	PF3D7_0206800	Taylor et al., 1995
Pv-specific			
PvAMA1	apical membrane antigen 1	PVX_092275	Chuquiyauri et al., 2015
PvMSP1 ₁₉	merozoite surface protein	PVX_099980	França et al., 2016b
PvRII	region II, Duffy binding protein	PVX_110810	França et al., 2016a
PvDBP RII	region II, Duffy binding protein	PVX_110810	Ntumngia et al., 2012
PvEBP	erythrocyte binding protein	PVX_110835	Hester et al., 2013; Menard et al., 2013
PvRBP 1a	reticulocyte binding protein 1a	PVX_098585	França et al., 2016a

Table 1. List of antigens in the multiplex bead-based assay panel

The assay was conducted as described in Wu et al (2019). Briefly, serum was eluted from DBS samples 130 (~1uL from 3mm punch) with overnight incubation on a shaker and used at final dilution of 1:400. 131 Approximately 1000 beads per antigen were added per well in 96-well flat bottom plates, and were washed 132 using a handheld magnetic washer (Bio-Plex®) before adding 50uL of the eluted serum samples and 133 controls, which included 2 positive controls for P. falciparum and P. vivax (pool of plasma from adults in a 134 hyperendemic malaria setting), and 1 negative control (European malaria-naïve blood donors). After 1.5 135 hours on a shaker, plates were washed three times with PBS-T buffer, and 50uL of 1:200 secondary antibody 136 (Jackson Immuno 109-116-098: Goat anti-human Fcy-fragment specific IgG conjugated to R-Phycoerythrin 137 (R-PE) was added before a further 1.5-hour incubation. After washing, samples were read using the Luminex 138 200 machine and net median fluorescence intensity (MFI) levels to all antigens were recorded for all samples. 139 Plate specific adjustments were performed based on the outcome of standard control curves generated 140 from positive control pools included on each plate. 141

142 Data analysis

Statistical analyses were performed using R version 3.6.3 and Graphpad Prism 8. IgG antibody responses recorded as net MFI values were analyzed using different methods. Quantitative continuous antibody response data (reported as log₁₀ MFI values) were analyzed in relation to clinico-epidemiological data, and compared for different groups (*i.e.*, by age group, study site or current malaria infection) using Student's ttest or one-way ANOVA Kruskal-Wallis test with Wilcoxon test for pairwise comparisons. Correlations between the levels of antibody responses as well as age and malaria positivity were analyzed using Spearman's rank correlation.

150 Determining seropositivity rates using single antigen responses

Binary outcomes for seropositivity to each antigen were determined through the computation of cut-off values in 2 ways: by using *a.*) a 2-component finite mixture model (FMM), and *b.*) a reference naïve/ negative population (NegPop; mean MFI plus three standard deviations). The FMM was computed using the mixEM

function in R mixtools package, where the model identifies a negative component by modelling the log MFI 154 of the entire dataset as two normally distributed populations and identifying a threshold value from the 155 modelled negative population (mean MFI plus three standard deviations). To evaluate the accuracy of these 156 classifications, we used samples from different known exposed and unexposed populations as validation 157 data (Table 2). The validation data included a P. falciparum and P. vivax-positive group with African positive 158 controls, as well as clinical samples from a Malaysia study (Fornace et al., 2019) and this study. The malaria-159 negative group consisted of European malaria-naïve samples, and Philippine malaria-negative samples from 160 individuals under 10 years of age in a 2017 cross-sectional study in Bataan (van den Hoogen et al., 2020a) 161 and this study. For the negative population model, the European samples were used as reference population. 162 Samples were considered seropositive for specific antigens if MFI values are higher than the antigen cutoff 163 values (mean MFI plus 3 standard deviations for each antigen). Sensitivity and specificity for identifying 164 current P. falciparum and P. vivax infection from this study and the validation dataset, as well as receiver 165 166 operating characteristics (ROC) curves were determined for the seropositivity results of each antigen from this approach (Supplementary Tables 1 and 2). 167

168 Applying machine learning techniques for multiplex analysis of antigen responses

Additionally, we evaluated supervised classification approaches utilizing data from multiple antigen 169 responses. We used machine learning techniques to assess the predictive ability of all or combinations of 170 antigens for determining recent and historical malaria exposure. The 8 Pf-specific antigens were the 171 covariates evaluated for P. falciparum exposure, along with age. For predicting P. vivax exposure, the 6 Pv-172 specific antigens were used as the covariates. Age data was not available for all the P. vivax training data, 173 and was therefore excluded. The training data used for these models, as detailed in Table 2, included the 174 validation dataset described, and to account for the observed age-dependent cumulative responses to the 175 antigens, the negative dataset included historical positives, which are data from survey participants aged 50 176 177 years and older from Malaysia and Philippines (assumed to have had some historical exposure), as well as 178 a random selection of Pf or Pv-negatives from all age groups from this current study. The historical positives were used as the positive training dataset for historical exposure, and the negative population training data 179 included the same negatives from the validation dataset. 180

Super Learner (SL) optimized with AUC (Area under the ROC Curve) was used as an ensemble modelling 181 algorithm to allow for evaluating multiple models simultaneously (Helb et al., 2015; Hubbard et al., 2013), 182 183 namely Random Forest (RF), k-Nearest Neighbor (kNN), generalized boosted models (GBM), Support Vector 184 Machine (SVM), and GLM with Lasso (glmnet). Feature selection with corP, that screens for univariate correlation, was also included for some component models (GBM, RF). The SL model gives a prediction 185 value that ranges from 0 to 1, and this can be used to obtain binary classification (*i.e.*, those with prediction 186 values higher than 0.5 were considered positive). A 20-fold cross-validation was performed for internal 187 validation to evaluate the performance of the fitted SL models using a portion of the training dataset withheld 188 from the model, and the whole training dataset. ROC curves were used to evaluate the outcome of predicted 189 values for the samples and were then compared to the single antigen performances. The performance of 190 each ML model, or base learner, in the SL ensemble was also assessed. For additional assessment of the 191 model performance, external validation was performed for the classification models through an independent 192 dataset from a Malaysia cross-sectional survey (Fornace et al., 2018), which used the same panel of P. 193 falciparum antigens (not available for P. vivax panel). 194

195 Evaluating model performance in identifying current Pf and Pv infections in this study

Antibody responses to antigens included in this study (in particular, PfGLURP R2, Etramp5.Ag1 and GEXP18) have been previously shown to be predictive of recent exposure to *P. falciparum* infection (Helb et al., 2015;

Training data used	N	Validation	Negative population	SuperLearner / Random Forest:	SuperLearner / Random Forest:	SuperLearner / Random Forest:	Random Forest	Random Forest	
		dataset "	model	Recent Pf exposure	Recent Pv exposure	Historical Pf exposure	Historical Pf exposure	Historical Pv exposure	
European naive controls	179	neg	_	_	-	-	_	-	
Positive controls									
African P. falciparum-positive	4	Pf+		+					
African <i>P. vivax</i> -positive	10	Pv+			+				
This study									
P. falciparum-positive subset	568	Pf+		+					
P. vivax microscopy-positive subset	46	Pv+			+				
Below 10 y.o. from Bataan	202	neg		_	-	_	_	-	
Historical positives aged ≥50y.o. from Occidental Mindoro and Palawan	711			-		+			
PfAMA1 and PfMSP1 ₁₉ seropositive subset	512						+		
PvAMA1 and PvMSP1 ₁₉ seropositive subset	324							+	
Randomly selected malaria-negatives from Palawan aged <50y.o.**	550			-	-				
Bataan study (van den Hoogen et al., 2020a)									
Below 10 y.o. from Bataan	73	neg		-	-	_	-	-	
Malaysia study (Fornace et al., 2019)									
P. falciparum-positive subset	17	Pf+		+					
P. vivax-positive subset	37	Pv+			+				
Historical positives aged ≥50y.o. from Malaysia 2	1581					+			
PfAMA1 and PfMSP1 ₁₉ seropositive subset	1479			-			+		
PvAMA1 and PvMSP1 ₁₉ seropositive subset	873			-				+	

Table 2. Training and validation data used in the classification models

* Finite mixture models (FMM) were derived from the entire ENSURE dataset (n=9132), and indicated validation dataset was used to determine receiver operating characteristics (ROC) curves for both FMM and Negative population models (seropositivity classifications from single antigens). For the supervised classification models, + means it was classified as positive for the model, and – means it is considered for negative classification. Abbreviations: Pf- P. falciparum, Pv- P. vivax, neg – malaria-negative; y.o.-years old

van den Hoogen et al., 2020c) and thus we assessed their performance using the malaria-positive samples 199 in this study (n=889). In addition to single antigens, the SL algorithm was used to generate predictive 200 outcomes based on different combinations of the covariates. The importance of the antigens in providing 201 accurate predictions were assessed by using 3 to 9 covariates at a time for the SL model (based on the 202 variable influence reported by the base learners used). The AUC values from the ROC analysis based on 203 training data and ENSURE malaria-positives data were compared among the single-antigen seropositivity 204 rates and machine learning predictions for recent exposure. For the P. vivax analysis, responses to all 6 205 antigens were evaluated as covariates. With Super Learner giving weights to multiple ML models assessed 206 simultaneously, we also employed for classification the individual ML models that were given the most weight 207 or importance, namely RF and GBM. 208

209 Estimating seroconversion rates and historical exposure

In line with previous studies, seropositivity of the cumulative exposure markers (AMA1, MSP1₁₉ for both P. 210 falciparum and P. vivax) were used to estimate seroconversion rates (SCR), or the rate at which seronegative 211 individuals become seropositive, and seroreversion rates (SRR), or the rate at which seropositive individuals 212 revert to being seronegative, by fitting the age-specific prevalence in each of the 3 study sites into reverse 213 214 catalytic models using likelihood ratio methods (Drakeley et al., 2005; Sepúlveda et al., 2015). 215 Seroprevalence data were fitted to models that allow for a change in SCR, and this was preferred if the likelihood ratio tests result in a significant change when compared to a model assuming constant SCR. The 216 predicted time of change in transmission is then analyzed. In addition to the AMA1 and MSP1₁₉ 217 seroprevalence based on FMM models, Random Forest classifications using the combined continuous data 218 of AMA1 and MSP1₁₉ net MFI values for both *P. falciparum* (Pf-RF:2-covar) and *P. vivax* (Pv-RF:2-covar) 219 were also used to generate seroprevalence curves used for the analysis. The positive training data used for 220 these RF models are subsets of the historical positives that were seropositive to both markers for each 221 species based on FMM cutoff values (Table 2). The Super Learner approach was also used to predict Pf and 222 Pv historical exposure using quantitative data from all the antigens, with analysis performed separately for 223 each species. 224

225 **Results**

226 Heterogeneity of antibody responses from the 3 collection sites

A total of 9132 samples from a health facility-based survey conducted from 2016 to 2018 (**Reyes et al., 2021**) were available for serological evaluation, with the majority (>70%) from Rizal, Palawan, where the monthly sampling spanned 2 years, while collection in the other sites Morong, Bataan and Abra de llog, Occidental Mindoro spanned 1 year. Females comprised more than 60% of the total number of participants, with higher proportions in Bataan and Occidental Mindoro, though individuals from all ages and gender groups were represented (Table 3).

Malaria infections were detected only in Palawan with ~50% of infections in participants of both sexes aged 233 under 10 years old (51.8% and 48.2% males and females, respectively). Of the 889 Plasmodium-positive 234 samples confirmed through either microscopy, RDT and/or PCR, 58.0% had P. falciparum, 12.4% had P. 235 236 vivax, 6.7% had mixed Pf+Pv infections, 6.1% had P. malariae, P. ovale and P. knowlesi, while species identification could not be confirmed for 16.8% of the PCR-positive samples. From the Pf and Pv malaria-237 positive individuals (n=707, including mixed infections), 388 (54.8%) had fever before or during the visit to 238 239 the health facility, 62.1% of which were aged 10 years and under. Conversely, 63.1% of the asymptomatic malaria infections were in individuals above 10 years old. 240

Firstly, we compared the magnitude of antibody responses to *P. falciparum* and *P. vivax* antigens from the 3 collection sites. Corroborating with the reported case prevalence in the area, we show that individuals

243

from Palawan consistently had the highest antibody levels to all antigens and in all age groups, followed by individuals from Occidental Mindoro then Bataan (Fig 2A, Supplementary Figure 1). 244

Table 3. Characteristics of study population by site

	Morong, Bataan		Abra de llog Mine	, Occidental doro	Rizal, Palawan			
Number of analyzed samples	87	77	16	83	65	72		
Female, %	628	(71.6%)	1101	(65.4%)	3734	(56.8%)		
Age, median (IQR)	26	(11-39)	28	(15-43)	13	(5-31)		
number (% in site)								
0 to 5	150	(17.1%)	150	(8.9%)	1900	(28.9%)		
6 to 10	63	(7.2%)	154	(9.2%)	1055	(16.1%)		
11 to 19	102	(11.6%)	234	(13.9%)	957	(14.6%)		
20 to 34	279	(31.8%)	508	(30.2%)	1222	(18.6%)		
35 up	283	(32.3%)	637	(37.8%)	1438	(21.9%)		
<i>Plasmodium-</i> positive by microscopy/RDT/PCR (% in site)*	0	(0.0%)	0	(0.0%)	889	(13.5%)		
<i>P. falciparum</i> -positive (by microscopy/RDT/PCR)*	0	(0.0%)	0	(0.0%)	595	(9.1%)		
<i>P. vivax-</i> positive (by microscopy/RDT/PCR)*	0	(0.0%)	0	(0.0%)	172	(2.6%)		
PCR-confirmed species ID, n (% in site)								
P. falciparum, Pf mono-infection	0	(0.0%)	0	(0.0%)	516	(7.9%)		
<i>P. vivax</i> , Pv mono-infection	0	(0.0%)	0	(0.0%)	110	(1.7%)		
Pf + Pv mixed infection	0	(0.0%)	0	(0.0%)	60	(0.9%)		
Other species (mono- or mixed infections)	0	(0.0%)	0	(0.0%)	55	(0.8%)		
With fever or history of fever (% in site)	69	(7.9%)	172	(10.2%)	2727	(41.5%)		
Symptomatic Pf and Pv infections*	0	(0.0%)	0	(0.0%)	388	(5.9%)		
Asymptomatic infections (no fever, <i>Plasmodium</i> -positive)*	0	(0.0%)	0	(0.0%)	428	(6.5%)		
Asymptomatic microscopy- positive Pf infections	0	(0.0%)	0	(0.0%)	132	(2.0%)		
Asymptomatic microscopy- positive Pv infections	0	(0.0%)	0	(0.0%)	35	(0.5%)		

* Numbers include all Plasmodium infections detected by microscopy, RDT and/or PCR. Some samples did not have enough material for further species identification by PCR, for which results were based on microscopy and/or RDT diagnosis, while some (n=149) were confirmed Plasmodium-positive only. Pf and Pv numbers reported include mixed infections, which were specified in the PCR-confirmed species ID breakdown.

All 5 Plasmodium species, including P. malariae (n=50), P. ovale (n=4) and P. knowlesi (n=1), were detected in Palawan, with some as co-infections with Pf and/or Pv.

While antibody levels increased with age in all sites, there were marked differences observed between sites. 245 Younger age groups from Bataan and Occidental Mindoro had similar magnitude for antigens Etramp5.Ag1, 246 PvAMA1, PvMSP1₁₉ and PvDBPRII, which were significantly lower than in individuals from Palawan (p<0.001). 247 The association between antibody levels and age as well as malaria positivity was then assessed for each 248 antigen for the Palawan population, and expectedly, those associated with cumulative exposure PfAMA1, 249 PfMSP1₁₉, PfGLURP R2, PvAMA1 and PvMSP1₁₉ were strongly correlated with age (Spearman's coefficient 250 >0.5, p<0.0001), while those associated with recent exposure to P. falciparum, Etramp5.Ag1 and GEXP18, 251 were less strongly associated (Spearman's coefficient of 0.39 and 0.42, respectively, p<0.0001), along with 252 other P. vivax markers (Figure 2B). Strong positive correlations in antibody responses to all antigens were 253 observed (Figure 2B), but the highest associations were between responses to antigens from the same 254 species. For the P. falciparum-specific antigens, Etramp5.Ag1, PfGLURP R2 and GEXP18 had the stronger 255

associations with current *P. falciparum* infection (Spearman's correlation coefficient ranging from 0.26 to
 0.27, p<0.0001), and PvMSP1₁₉ and PvDBPRII showed weak correlation (Spearman's coefficient of 0.13 and
 0.12, respectively, p<0.0001) for current *P. vivax* infection.

Similarly, mean antibody levels were higher in a species-specific manner (Figure 3); Etramp5.Ag1, PfGLURP R2 and GEXP18 showed significantly higher antibody levels in those with active Pf infections (p<0.0001) and PvMSP1₁₉ antibody levels were highest in *P. vivax*-positive cases (p<0.001), with better resolution in younger age groups. Taken together, our results confirm the applicability of these serological markers in differentiating areas of varying malaria endemicity, and there were species-specific associations with current infection.





- A. Antibody levels (reported as log10 MFI) in response to *P. falciparum* cumulative and recent exposure markers PfAMA1, PfMSP1₁₉, and Etramp5.Ag1, and *P. vivax* serological markers PvAMA1, PvMSP1₁₉ and PvDBP.RII by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).</p>
- B. Spearman's correlation coefficients for age, malaria diagnosis (Mal+: Plasmodium-positive, Pf+: *P. falciparum*-positive, Pv+: *P. vivax*-positive), and antibody responses to the 14 antigens in the panel for Palawan samples (n=6572).



Figure 3. Serological markers exhibit species-specific association with current infection in varying levels A-B) Comparison of antibody titers of Palawan samples (n=6572) for *Plasmodium*-positive (Pf: P. falciparum-positive, Pf/Pv: Pf and Pv mixed infection, Pv: P. vivax-positive) and negative (neg) samples by age group in each *P. falciparum*-specific (A) and *P.vivax*-specific antigen.

268 Identifying markers of recent falciparum and vivax malaria exposure and current infection

Next, we applied different analytical approaches to ascertain whether the serological markers can be used 269 to predict recent or historical exposure. We first assessed the performance of responses to single antigens 270 271 in determining binary outcomes for seropositivity by estimating cutoff values using finite mixture models (FMM) and negative population models that represented unsupervised and supervised classification models, 272 respectively (Figure 4A & 4B, Supplementary Tables 1 & 2). Seropositivity results were then compared with 273 P. falciparum and P. vivax positivity, as assessed by microscopy, RDT or PCR. The resulting seropositivity 274 cutoff values were comparable for both models, with AUC values from the validation data ranging from 0.812 275 to 0.932 for the 8 P. falciparum markers, and 0.534 to 0.943 for the 6 P. vivax markers. 276

- When evaluated in classifying study samples, AUC values ranged from 0.497 to 0.756 for P. falciparum 277 markers and 0.513 to 0.731 for P. vivax markers, showing low predictive ability for some of the markers, 278 although previously reported recent exposure markers Etramp5.Ag1 and GEXP18 for P. falciparum and 279 PvMSP1₁₉ for *P. vivax*, had significantly higher AUC values (>0.735, p<0.002) compared to the rest of the 280 markers analyzed (ranged from 0.4971 to 0.7065) (Supplementary Tables 1 & 2). Density plots of antibody 281 responses also show an overlap in samples from malaria-negative and positive individuals, contributing to 282 the lower AUCs (Supplementary Figure 2) though overall seropositivity to antigens matched with 79.2% of 283 the falciparum-positive and 60% of the vivax-positive cases in the project dataset. Proportions of samples 284 seropositive to at least 4 of the 8 Pf markers and at least 3 of 6 Pv markers were 5.02% and 5.70% for Bataan, 285 30.96% and 25.85% for Occidental Mindoro, and 53.90% and 40.03% for Palawan, respectively. 286 Seroprevalence rates for all antigens were consistently low in Bataan in all age groups as shown in Figures 287 4A & 4B, with recent exposure markers (hollow circles) estimating lower rates, consistent with their lower 288 correlation with age and lower likelihood of exposure to infection in this setting. 289
- To analyze the multi-antigen continuous antibody data, we used supervised machine learning methods for 290 antibody responses to antigens for both species. The Super Learner (SL) ensemble machine learning 291 algorithm was used to simultaneously evaluate machine learning models, which included Random Forest 292 293 (RF), k-Nearest Neighbor (kNN), generalized boosted models (GBM), Support Vector Machine (SVM), and GLM with Lasso (glmnet), in predicting recent and historical malaria exposure through the resulting weights 294 applied to each learner after cross-validation. Different combinations of covariates were assessed for their 295 relative importance for the model using the ROC curves of the cross-validated predictions (Figure 4C & 4D; 296 297 Supplementary Tables 1 & 2). A 9-covariate model (SL: 9-covar) was evaluated for the Pf panel, which had 298 the antibody responses to 8 antigens and age as covariates. This model had the highest AUC among all SL models, with a value of 0.9898 (95% CI 0.9874-0.9921) and 0.9197 (95% CI 0.9093-0.9302) for the binary 299 classification predictions for the training data and test data, respectively. It was able to correctly identify 300 71.1% of the P. falciparum-positive individuals from this study (Supplementary Table 1). Removing the age 301 as covariate (SL:8-covar model) decreased the prediction capacity of the model for the test data, with 53.3% 302 of the P. falciparum infections identified. For predicting P. vivax recent exposure, i.e., confirmed Pv infections, 303 the 6 Pv antigens were used as covariates for the SL model (SL:6-covar) and had a resulting AUC of 0.8857 304 (95% CI 0.8429-0.9284) and 0.6332 (0.5979-0.6686) for validation data and test data, respectively 305 (Supplementary Table 2). 306
- Super Learner assigns weights to each machine learning model included in the ensemble algorithm after cross-validation, and for both Pf and Pv exposure predictions, generalized boosted models with or without feature selection (GBM and GBM_corP) were given the highest weights, followed by 3 included variations of the RF model (RF, RF-ranger and RF-ranger_corP) (Supplementary Figure 3A & 3B). However, upon using 20-fold nested cross-validation and closer inspection of the classification accuracy of the individual learners, the Random Forest (RF) models were found to have the highest AUCs for predicting *P. falciparum* recent infections in both the validation data (not shown) and test data (Supplementary Figure 3C), while component



Figure 4. Analysis of serological markers through machine learning methods improves classifications for recent *P. falciparum* and *P. vivax* exposure or current infection

- A-B. Seropositivity rates of sample population by site and age group based on cutoff values from finite mixture models (FMM) and negative population model (NegPop) for Pf and Pv antigens (detailed in Supplementary Tables 1 and 2). Hollow dots represent the FMM and Negpop seropositivity rates for the two reported recent exposure markers Etramp5.Ag1 and GEXP18 for Pf (A), and PvMSP1₁₉ and PvDBP.RII for Pv (B) panel. Lines with error bars represent median with 95% CI.
- **C-D.** Receiver operating characteristic (ROC) curves for the antibody responses to single antigens for individual antigens, and for the SL models (shown in both as binary outcomes of seropositivity / prediction values).
- E-F. Variable importance of the 8 Pf-specific (E) and 6 Pv-specific (F) antigens based on the Random Forest model.
 G. Predicted rates of recent Pf exposure based on analysis of the continuous antibody responses of the 8-antigen panel using Super Learner. Each hollow dot represents differences in the number of covariates used for the model (3, 4, 8, 9), as well as 2 showing rates from prediction values of the Random Forests (RF) component model (RF.covar4 and RF.covar8 in solid dots).
- H. Predicted rates of recent Pv exposure based on analysis of the continuous antibody responses of the 6-antigen panel using Super Learner. Dots represent the positivity rates from the prediction values of the SL model, and the individual predictions from the 2 most weighted base learners in the resulting model – RF and GBM. RF predictions (RF.covar6) are shown as solid dots.

(SL: Super Learner, RF: random Forest, covar#: number of covariates included in the model, FMM: finite mixture models; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 with significance assessed by one-way ANOVA followed by Tukey's multiple comparison)

models for classifying vivax malaria infections had similar AUCs, ranging from 0.701 to 0.8 for test data (Supplementary Figure 3D).

- The Super Learner ensemble model did not show any increase in classification accuracy compared to RF, 316 which suggests that RF is the best performing model in distinguishing current or recent falciparum malaria 317 infections. Still, both SL and SL-RF (RF prediction within the SL ensemble) predictions from the Pf panel had 318 highly improved AUCs compared to single antigen classifications based on finite mixture models (Figure 4C), 319 while model predictions for the Pv panel had comparable AUCs, and machine learning models did not 320 improve the AUC predictions (Figure 4D). Variable importance in the RF model shows that responses to 321 Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1₁₉ had the highest influence in the predictions for P. 322 falciparum positivity (Figure 4E), while PvMSP1₁₉ and PvAMA1 were the most predictive P. vivax antigens 323 (Figure 4F). Using the top 3 antigens (SL:3-covar - PfGLURP R2, Etramp5.Ag1, GEXP18) and top 4 (SL:4-324 covar, which included PfMSP1₁₉) as covariates resulted in further lowered AUC values with 0.8790 and 325 0.8967, respectively, and identified >50% of the *P. falciparum* cases (Supplementary Table 1). 326
- Performing Random Forest models outside SL (using Random Forest package) had the same predictions as 327 SL-RF, and using the 4 covariates Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1₁₉ (RF.covar4) gave an 328 AUC of 0.9983 for the training data and 0.9591 for the test data – the highest for all Pf models tested (Figure 329 3C; Supplementary Table 1). The RF.covar4 model was able to accurately identify 92.8% of the P. falciparum 330 infections in our data, and had a comparable AUC with the RF 8-covariate model (RF.covar8), showing that 331 analysis using the 4 antigens is sufficient for predicting recent P. falciparum infection or exposure (Figure 332 3C; Supplementary Table 1). Meanwhile, predictions of *P. vivax* recent exposure were also not different for 333 the SL, RF and GBM models (Figure 4D; Supplementary Table 2). 334
- The predictive performance of the resulting SL models (SL:3-covar, SL:4-covar, SL:8-covar, SL:9-covar for Pf exposure predictions, and SL:6-covar for Pv exposure predictions) were then compared with RF (both species) and GBM (for Pv) predictions (RF.covar4 and RF.covar8 for Pf; RF.covar6 and GBM.covar6 for Pv) (Figure 4G & 4H), and the rates of predicted current *P. falciparum* infection based on SL and RF models all consistently gave 0-0.2% prediction for Occidental Mindoro and Bataan, where no *P. falciparum* malaria cases were reported in recent years, suggesting that these models can accurately predict the absence of recent falciparum malaria exposure and infection (Figure 4G). Analysis of antibody responses to *P. vivax*



Figure 5. Seroconversion curves based on reverse catalytic models using AMA1 and MSP1₁₉ antibody responses provide accurate estimates of historical exposure. Age-specific seroprevalence was based on finite mixture models and Random Forest models (using both antigens: RF 2-covar models) for each species. Solid lines represent the fit of the reversible catalytic models, dashed lines represent 95% confidence intervals, and dots represent the observed proportions of seropositives per age divided into 10% centiles. For models assuming a change point in transmission, only the recent seroconversion rates and change point estimates (in years) are shown, while the historical seroconversion rates and seroreversion rates are detailed in Table 4.

antigens also had <1% prediction rate for Bataan and <5% for Occidental Mindoro, also indicative of the absence of recent *P. vivax* infections in these sites (Figure 4H; Supplementary Table 2).

To further evaluate the performance of the RF 4-covariate model for predicting P. falciparum recent 344 exposure, external validation was performed using an available test dataset that included samples from a 345 cross-sectional survey in Malaysia (n=8163; Fornace et al., 2018), PCR-validated malaria cases (Pf=47, non-346 Pf=423), and malaria-naïve or malaria-negative samples (n=511). The model prediction resulted in an AUC 347 of 0.93 (CI 0.8817-0.9782), and was able to predict 0.47% prevalence of infection for the cross-sectional 348 survey, correctly identifying 41 of 47 (87.2%) of the *P. falciparum* PCR-confirmed cases seen in the survey. 349 The observation that this relatively simple model was able to provide accurate predictions for both the 350 Philippine and Malaysian datasets suggests potential as a robust indicator for recent exposure and current 351 infections, in areas with varying levels of transmission. 352

353 Estimating P. falciparum and P. vivax historical exposure

AMA1 and MSP1₁₉ responses for *P. falciparum* and *P. vivax* have been widely used to assess historical

		Bataan	Occidental Mindoro	Palawan			
PfAMA1	SCRhistorical	0.02102 (0.00599 - 0.07375)	0.03306 (0.02150 - 0.05082)	0.06953 (0.06251 - 0.07736)			
	SCRrecent	0.00193 (0.00112 - 0.00332)	0.01024 (0.00707 - 0.01483)	0.13346 (0.11802 - 0.15092)			
	SRR	0.010002 (0.0010 - 0.10353)	0.01239 (0.00575 - 0.02673)	0.00841 (0.00626 - 0.01129)			
	Time of change in transmission (yrs)	29	12	2			
PfMSP1 ₁₉	SCRhistorical	0.04042 (0.00836 - 0.19516)	0.03399 (0.02221 - 0.05204)	0.07521 (0.06658 - 0.08495)			
	SCR _{recent}	0.00243 (0.00148 - 0.00396)	0.01412 (0.00842 - 0.02367)	0.14811 (0.13109 - 0.16734)			
	SRR	0.01959 (0.00564 - 0.06796)	0.01779 (0.00926 - 0.03416)	0.01221 (0.00946 - 0.01575)			
	Time of change in transmission (yrs)	33	7	2			
RF with	SCRhistorical	0.01513 (0.00426 - 0.05370)	0.03338 (0.02172 - 0.05130)	0.06836 (0.06133 - 0.07619)			
PfMSP1 ₁₉	SCR _{recent}	0.00122 (0.00064 - 0.00234)	0.00931 (0.00630 - 0.01377)	0.12847 (0.11333 - 0.14564)			
	SRR	0.00463 (0.00002 - 0.91264)	0.01327 (0.00639 - 0.02755)	0.00901 (0.00674 - 0.01204)			
	Time of change in transmission (yrs)	29	12	2			
PvAMA1	SCRhistorical	0.07078 (0.01619 - 0.30943)	0.02760 (0.02094 - 0.03638)	0.05210 (0.04652 - 0.05834)			
	SCRrecent	0.00197 (0.00102 - 0.00377)	0.00840 (0.00451 - 0.01564)	0.08800 (0.07591 - 0.10202)			
	SRR	0.03138 (0.01524 - 0.06460)	0.00715 (0.00269 - 0.01898)	0.01074 (0.00801 - 0.01441)			
	Time of change in transmission (yrs)	29	7	2			
PvMSP119	SCRhistorical	0.02858 (0.00465 - 0.17570)	0 01143 (0 00921 - 0 01419)	0.03760 (0.03172 - 0.04458)			
	SCRrecent	0.00178 (0.00092 - 0.00347)	0.01140 (0.00321 - 0.01413)	0.08687 (0.07507 - 0.10052)			
	SRR	0.02941 (0.00862 - 0.10026)	0.00404 (0.00047 - 0.03486)	0.02146 (0.01599 - 0.02880)			
	Time of change in transmission (yrs)	28	-	2			
RF with	SCRhistorical	0.03387 (0.00559 - 0.20521)	0 01130 (0 00010 - 0 01/1/)	0.04023 (0.03472 - 0.04661)			
PvMSP119	SCRrecent	0.00169 (0.00084 - 0.00340)	0.01109 (0.00313 - 0.01414)	0.08479 (0.07313 - 0.09833)			
	SRR	0.03498 (0.01265 - 0.09673)	0.00388 (0.00042 - 0.03598)	0.02227 (0.01674 - 0.02963)			
	Time of change in transmission (yrs)	28	-	2			

Table 4. Seroconversion and seroreversion rates from reverse catalytic models in each study site

Seroconversion rates (SCR) and seroreversion rates (SRR) are presented for *P. falciparum* and *P. vivax* based on reverse catalytic models using agespecific seroprevalence from finite mixture models with AMA1 and MSP1₁₉ and Random Forest (RF) 2-covariate models. If the best reverse catalytic model to fit the age-adjusted seropositivity data was one with no change point in transmission, only 1 SCR is indicated, while if the best fit is one with a change point, the SCR before the change point is indicated as SCR_{historical} and the SCR after the change point is indicated as SCR_{recent}. The estimated change point in transmission (in years) is also indicated.



- **C.** Distribution of antibody responses to PfAMA1 by site and age of individuals (n=9132). Red dashed line represents the seropositivity cutoff value from the FMM model.
- **D-E.** Summary graphs per age category per site of SL-predicted Pf historical exposure (D) and PfAMA1, PfMSP1 seropositivity rates graphed with estimated historical exposure rates using the Random Forest model with PfAMA1, PfMSP1₁₉ as covariates (E).
- **F.** Summary graph of PvAMA1, PvMSP1 seropositivity rates with estimated historical exposure rates using the Random Forest model with PvAMA1, PvMSP1₁₉ as covariates seropositivity per age category per site

exposure by estimating seroconversion and seroreversion rates. Using reverse catalytic models and maximum likelihood tests on the age-specific seroprevalence based on the FMM model seropositivity rates for PfAMA1, PfMSP1₁₉, PvAMA1 and PvMSP1₁₉, we estimated the time of interruption of transmission in our study area (Figure 5, Table 4).

The Random Forest algorithm was also employed to generate models that make use of both cumulative exposure antigens (2-covariate models for the 2 species: Pf-RF:2-covar and Pv-RF:2-covar), and the predicted binary outcomes were also used in the reverse catalytic models. Most of the seroconversion curves were best fit with a model assuming a change in transmission based on log likelihood tests (p <0.001), except for PvMSP1₁₉ (p= 0.507) and the RF-Pv model (p=0.285) with PvAMA1 and PvMSP1₁₉ as covariates (Table 4).

Based on these models, the time of change in transmission in Bataan was estimated at 29-33 years for *P. falciparum* and 28-29 years for *P. vivax*. Occidental Mindoro had varied estimates of the change point (7 and 12 years), while PvMSP1₁₉ and consequently the RF Pv 2-covar model did not better fit in the model assuming a change in transmission. For these 2 provinces, the seroconversion rates were decreased after the change point, suggesting a decrease in transmission, while for Palawan, an increase of the seroconversion rates was observed in all models after the 2-year change point, suggesting that there was an increase in transmission in this study site.

We further explored whether the use of the SL model can provide improved estimates of historical exposure. 373 The 8 Pf antigens and 6 Pv antigens were separately used as covariates, and the binary classification derived 374 from the SL prediction values for each site by age group were then compared with the single antigen 375 seropositivity rates and RF 2-covariate models' estimated exposure rates (Figure 6A & 6C, summarized in 376 Figure 6D & 6E, respectively). The contribution of each covariate based on the RF model (Figure 6B), as 377 expected, showed that the antigens associated with long-lived antibody responses – AMA1 and MSP1₁₉ – 378 had the highest influence in the prediction for both P. falciparum and P. vivax historical exposure. However, 379 comparing the SL-predicted rates with seropositivity rates of the top Pf antigen PfAMA1 (Figure 6A & 6B) 380 show that SL overestimated historical exposure, with higher-than-expected positivity rates observed in 381 382 younger age groups from Bataan and Occidental Mindoro where transmission is reportedly absent (Figure 6E). The seropositivity rates based on the 2-covariate RF models with AMA1 and MSP1₁₉ seem to provide 383 better estimates of historical exposure to both P. falciparum and P. vivax based on known malaria prevalence 384 of the sites than the SL models that included all antigens (Figure 6E & 6F). 385

386 Discussion

In this study we assessed the utility of multiple antigen specific antibody responses and different statistical 387 methods to estimate both current malaria infection and historical transmission in areas of different 388 endemicity in the Philippines. Using a multiplex bead-based assay with a panel of 8 P. falciparum-specific 389 and 6 P. vivax-specific recombinant antigens, we showed that whilst antibody levels to most antigens 390 described broad differences in transmission, Random Forest predictions with 4 P. falciparum-specific 391 antigens (Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1₁₉) accurately identified >90% of P. falciparum 392 infections in the data. Rates of predicted infection with these models were also highly consistent with ongoing 393 levels of transmission described by routine data. Similar observations were made for P. vivax with 2 antigens 394 (PvMSP1₁₉ and PvAMA1) but with lower precision. Moreover, reconstruction of historical transmission 395 patterns was improved by combining seropositivity to two antigens (MSP1₁₉ and AMA1 for both P. falciparum 396 and P. vivax) assessed using finite mixture models, and further improved using the Random Forest model 397 on continuous data from these antigens combined. These findings highlight the potential for advanced 398

analysis of multiplex serological data to provide additional accurate data on incidence levels that could be
 used by control programs at small spatial scales.

- The use of multiple antigens to assess exposure to malaria infection circumvents some issues related to 401 genetic diversity in the parasite and variation in the human immune response to different antigenic targets. 402 The approach also allows application of more advanced statistical analysis to examine optimal combinations 403 of antibody responses in predicting specific outcomes. Here, in addition to the well-studied antigens AMA1 404 and MSP1₁₉, we screened other antigenic markers that have been reported to accurately predict recent 405 exposure in studies in Africa and the Caribbean (Helb et al., 2015; van den Hoogen et al., 2020c; Wu et 406 al., 2020a). We then employed a machine learning approach for predicting classification outcomes of 407 disease exposure which has been used previously to analyze antibody response data (Helb et al., 2015; 408 Longley et al., 2020; Rosado et al., 2020). We showed that the machine learning models were able to both 409 confirm the absence of current infection in Occidental Mindoro and Bataan, and, using the Random Forest 410 predictions from a 4-covariate model including PfGLURP R2, Etramp5.Ag1, GEXP18 and PfMSP1₁₉, 411 accurately identify >92% of the Plasmodium-positive study samples from this study, whether detected 412 through microscopy, RDT and/or PCR. The relative simplicity of this model and lack of requirement for basic 413 epidemiological variables such as age is a benefit in assessing current infection and recent exposure, 414 including stable transmission settings (*i.e.*, like in Palawan with an API of >5 for the whole province, and >30 415 416 for the study site Rizal). We expected that the Super Learner model would improve the predictions with its ensemble approach; however, for predicting P. falciparum current infections in particular, RF-based models 417 had the better AUC for both training and test data. This was not the case for the P. vivax current infection 418 predictions, which showed similar AUCs (<0.7) for the final SL model and its component models. RF variable 419 importance showed that PvMSP1₁₉ was the most predictive among the 6 antigens in our panel, which is 420 consistent with the recent study by Longley et al (2020), likewise utilizing a RF prediction algorithm that 421 identified PvMSP1₁₉ as one of the 8 most predictive P. vivax recent exposure markers. It is likely that the low 422 AUC and predictive ability we observed is a limitation of the panel of antigens available to us at the time of 423 the study rather than the analytical approach itself. Notwithstanding, the SL approach was able to provide 424 the means for evaluating multiple supervised machine learning models simultaneously, and, for the purpose 425 of accurately distinguishing recent exposure from historical exposure with high sensitivity, the RF model 426 seems to be the most predictive. The satisfactory results from the external validation using the cross-427 sectional survey data from Malaysia also suggests broader utility not least in neighboring Southeast Asian 428 countries with similar historical transmission patterns. 429
- In stratification of malaria transmission, a key component is determining its absence. In many countries 430 including the Philippines, malaria-endemic provinces apply for malaria-free status when indigenous or local 431 cases have not been reported for a set number of years, typically 3 or more. More rapid, subnational 432 433 demonstration of the absence of exposure could aid in this process. Cumulative exposure markers are used in various studies to estimate malaria transmission intensities, wherein age-specific seroprevalence can be 434 used to confirm the level of historical exposure of endemic areas. Malaria-specific serological assays can 435 then be utilized for determining the absence of transmission by evaluating antibody responses of populations. 436 In assessing the individual performances of recent exposure markers, it can be observed that younger age 437 438 groups in Bataan reported <10% seropositivity, although this province has not reported indigenous cases since 2011, and this may be attributed to background seropositivity. Moreover, the lower seropositivity rates 439 observed in younger age groups in Palawan may be attributed to children who have not yet developed 440 adequate IgG responses for detection in a serological assay. Nevertheless, our results provide an alternative 441 approach using a multiplex analysis of 4 predictive P. falciparum serological markers that was able to 442 improve the computation of binary outcomes for accurately predicting current or recent falciparum malaria 443 infections. 444

Strong correlations among the P. falciparum and P. vivax antigens in the panel were observed, consistent 445 with previous observations (Chotirat et al., 2021; Rogier et al., 2021) and suggesting the combined risk of 446 P. falciparum and P. vivax infection in Rizal, Palawan. Nonetheless, our results also indicate that the P. 447 falciparum-positive and P. vivax-positive samples had species-specific increase and significantly different 448 patterns in its antibody responses to the P. falciparum and P. vivax-specific antigens. The simultaneous 449 cumulative increase in species-specific antibodies has been explored for its possible role in the development 450 of cross-protective immunity (Gnidehou et al., 2019; Mitran and Yanow, 2020; Muh et al., 2020), and can 451 be an area for further investigation, as this could potentially explain the observed asymptomatic PCR-only 452 cases (including mixed infections) in Rizal, Palawan (Reves et al., 2021). 453

- This study had a number of limitations. Since the study analyzed samples from a health facility-based survey, 454 455 whether or not it accurately represents the populations needs to be assessed. Due to the nature of the survey we were only able to sample health-seeking individuals, though this was partially addressed by also 456 recruiting companions of patients who visited the health facilities (Reyes et al., 2021). For predicting recent 457 infections, we had not asked survey participants if they recently had malaria, or if they had past malaria 458 episodes for that matter (self-reported malaria history), such that we have only attempted to predict current 459 infections. Still, external validation of our prediction algorithm for P. falciparum infection confirms its 460 promising performance in accurately predicting malaria infections. 461
- There are also no accessible detailed records of the malaria history of individual visitors in the health facilities, 462 such that the results for the predicted historical exposure cannot be validated. Nonetheless, we are able to 463 show that consistent with previous studies (Biggs et al., 2017; Idris et al., 2017; Perraut et al., 2014; 464 Rosas-Aguirre et al., 2015; Wu et al., 2020b), seropositivity rates from cumulative exposure markers AMA1 465 and MSP1₁₉ for *P. falciparum* and *P. vivax* seemed to agree with the known malaria situation of our study 466 sites. The "historical positives" used as training data for predicting historical exposure were the adult 467 population (aged 50 years old and above) in malaria-endemic areas, wherein we assumed that all these 468 individuals were exposed at some point, and that their antibody profiles would reflect historical exposure. 469 The high variations in the dataset would have greatly affected these predictions. Since the reference 470 population data available for predicting historical exposure using supervised classification approaches was 471 not suitable, using the unsupervised approach of determining AMA1 and MSP1₁₉ seropositivity rates based 472 on FMM may then suffice. Based on the known malaria situation in the collection sites, results from the SL 473 474 model, RF 2-covar model and individual seropositivity rates of AMA1 and MSP1₁₉ may be able to provide a reliable estimate of malaria exposure in the area. The seroconversion rates also reflect the transmission 475 status of our sites, with Bataan having the lowest, followed by Occidental Mindoro, and highest for Palawan. 476 Our results are able to confirm the absence of P. falciparum and P. vivax transmission in malaria-free Bataan 477 for the age groups 10 and below, providing evidence for its malaria elimination status. Moreover, the change 478 479 point in transmission for Bataan is estimated higher but still consistent with the results of a serological survey conducted in the same area a year prior, which estimated the change point at 22 years (van den Hoogen 480 et al., 2020a), and coincided with the decline in cases in the municipality. For Occidental Mindoro, the 481 interruption in transmission from 7-12 years ago may be explained by the extensive malaria control activities 482 implemented in the area, as the province has been part of the priority provinces of the Global Fund for 483 484 Malaria since the 2000s. Our seroconversion curve results also suggest an increase in malaria transmission in Rizal, Palawan during the time of our survey (2016 to 2018), and upon checking the numbers of the 485 reported malaria cases, there was indeed a steady rise of the API in this municipality from 25.43 in 2014, 486 33.97 in 2015, to 46.09 in 2016 and 56.78 in 2018. 487

The longevity of IgG antibody responses to malaria-specific antigens has the potential to also provide information on the development of naturally acquired immunity in populations (**King et al., 2015**) – although if and how assay responses translate to immune protection is not well understood (**Crompton et al., 2010**;

Projetti et al., 2019; Stanisic et al., 2015). From the 3 sites in the study, we were able to detect Plasmodium 491 infections only in Rizal, Palawan. Asymptomatic infections comprised 265 (44.5%) of the malaria cases 492 detected, and were observed in all age groups, which suggests the development of clinical immunity in this 493 endemic population with relatively stable transmission. Our results showed that >80% of the PfAMA1 494 seropositives in Bataan had lived there for >10 years, and had net MFI levels that were comparable with 495 adults in Occidental Mindoro and Palawan (data not shown), suggesting that what we observed could be 496 long-lived antibody responses to P. falciparum and P. vivax malaria in the population. Still, the lower 497 seropositivity rates in Bataan and Occidental Mindoro, areas which had high transmission 20 and <10 years 498 ago, respectively, may highlight the impact of a reduced transmission in malaria immune responses. Still, 499 our data supports the notion that long-lived antibodies can be maintained even in the absence of ongoing 500 transmission. Of interest for countries aiming for elimination is evaluating the impact of a decrease in 501 transmission on the immunity or vulnerability of a population, especially in differing endemic settings 502 503 (Fowkes et al., 2016; World Health Organization, 2017). Understanding the generation and maintenance of effective immune responses during natural infection, particularly in the era of changing malaria 504 epidemiology, is crucial for the rational development and evaluation of future interventions and vaccines. 505 Immunological studies are needed to investigate this further. 506

Despite the mentioned limitations of the study, our results clearly show the potential use of multiplex antibody 507 508 responses and applications of machine learning approaches in assessing malaria transmission for countries 509 aiming for malaria elimination. In a sub-national elimination setting such as the Philippines, both recent and historical P. falciparum and P. vivax exposure metrics were indicative of the absence of recent transmission 510 in Bataan and Occidental Mindoro, and were also able to identify current infections in Rizal, Palawan, thus 511 showing its ability in assessing the malaria situation in varying areas of endemicity. These serological 512 markers provide accurate estimates of recent and historical exposure to malaria and our study provides 513 baseline immunological data for monitoring risk populations. This serological surveillance approach can aid 514 in devising control measures by malaria elimination programs, as well as provide evidence of the 515 effectiveness of programs being implemented. 516

517 Acknowledgements

This study was supported by the Newton Fund, Philippine Council for Health Research and Development, 518 and UK Medical Research Council through funding received for ENSURE: Enhanced surveillance for control 519 and elimination of malaria in the Philippines (MR/N019199/1). We also express our gratitude to the ENSURE 520 team, specially Carol Joy Sarsadiaz, Hennessey Sabanal, Beaulah Boncayao and Ellaine de la Fuente who 521 assisted in the conduct of serological assays for this project, as well as Dr. Mario Jiz, Dr. Catalino Demetria, 522 and Dr. Marilou Nicolas who provided technical assistance and access to their Luminex 200 instruments. 523 Also, we thank the local government and health staff of Palawan, Occidental Mindoro and Bataan for their 524 invaluable support to our research. This work is also supported by the Nagasaki University "Doctoral 525 Program for World-leading Innovative and Smart Education" for Global Health, "Global Health Elite 526 Programme for Building a Healthier World". 527

528 Author Contributions

529 CJD, FEJE, JCRH, and MLMM conceived and designed this study. MLMM, KMF and CJD analyzed and 530 interpreted the data. MLMM wrote the first draft of the manuscript with support from KMF, CJD, JCRH, KY, 531 and FEJE. JSL, RAR, MLMM, and APNB supervised the data and sample collection, and the conduct of 532 assays. KKAT, JHA, CH, and CEC provided the recombinant antigens used for the multiplex bead-based 533 assay. MLMM and RAR performed the serological assays with support from TH and KKAT. All authors read 534 and approved the final manuscript.

535 **Competing interests**

536 The authors declare no competing interests.

537 **References**

- Biggs J, Raman J, Cook J, Hlongwana K, Drakeley C, Morris N, et al. Serology reveals heterogeneity of
 Plasmodium falciparum transmission in northeastern South Africa: Implications for malaria elimination. *Malar J* 2017;16. https://doi.org/10.1186/s12936-017-1701-7.
- Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium
 falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. *Mol Biochem Parasitol* 1994;64:165–9. https://doi.org/10.1016/0166-6851(94)90144-9.
- Chotirat S, Nekkab N, Kumpitak C, Hietanen J, White MT, Kiattibutr K, et al. Application of 23 novel serological
 markers for identifying recent exposure to Plasmodium vivax parasites in an endemic population of
 western Thailand. *MedRxiv* 2021:2021.03.01.21252492.
- Chuquiyauri R, Molina DM, Moss EL, Wang R, Gardner MJ, Brouwer KC, et al. Genome-scale protein microarray
 comparison of human antibody responses in plasmodium vivax relapse and reinfection. *Am J Trop Med Hyg* 2015;93:801–9. https://doi.org/10.4269/ajtmh.15-0232.
- Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW, Blackman MJ. Fine mapping of an
 epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical
 membrane antigen 1. *J Biol Chem* 2007;282:7431–41. https://doi.org/10.1074/jbc.M610562200.
- Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator of malaria transmission intensity? *Trends Parasitol* 2007;23:575–82. https://doi.org/10.1016/j.pt.2007.08.023.
- Coutts SP, King JD, Pa'au M, Fuimaono S, Roth J, King MR, et al. Prevalence and risk factors associated with
 lymphatic filariasis in American Samoa after mass drug administration. *Trop Med Health* 2017;45:1–10.
 https://doi.org/10.1186/s41182-017-0063-8.
- Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab
 response to Plasmodium falciparum before and after a malaria season by protein microarray. *Proc Natl Acad Sci U S A* 2010;107:6958–63. https://doi.org/10.1073/pnas.1001323107.
- Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro I, et al. Estimating medium- and
 long-term trends in malaria transmission by using serological markers of malaria exposure. *Proc Natl Acad Sci* 2005;102:5108–13. https://doi.org/10.1073/pnas.0408725102.
- Folegatti PM, Siqueira AM, Monteiro WM, Lacerda MVG, Drakeley CJ, Braga ÉM. A systematic review on
 malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure
 and protection. *Malar J* 2017;16:107. https://doi.org/10.1186/s12936-017-1762-7.
- Fornace KM, Brock PM, Abidin TR, Grignard L, Herman LS, Chua TH, et al. Environmental risk factors and
 exposure to the zoonotic malaria parasite Plasmodium knowlesi across northern Sabah, Malaysia: a populationbased cross-sectional survey. *Lancet Planet Heal* 2019;3:e179–86. https://doi.org/10.1016/S25425196(19)30045-2.
- Fornace KM, Herman LS, Abidin TR, Chua TH, Daim S, Lorenzo PJ, et al. Exposure and infection to Plasmodium
 knowlesi in case study communities in Northern Sabah, Malaysia and Palawan, The Philippines. *PLoS Negl Trop Dis* 2018;12:e0006432. https://doi.org/10.1371/journal.pntd.0006432.
- Fouda GG, Leke RFG, Long C, Druilhe P, Zhou A, Taylor DW, et al. Multiplex assay for simultaneous
 measurement of antibodies to multiple Plasmodium falciparum antigens. *Clin Vaccine Immunol* 2006;13:1307–
 https://doi.org/10.1128/CVI.00183-06.
- 577 Fowkes FJI, Boeuf P, Beeson JG. Immunity to malaria in an era of declining malaria transmission. *Parasitology* 578 2016;143:139–53. https://doi.org/10.1017/S0031182015001249.
- Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and
 incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. *PLoS Med* 2010;7.
 https://doi.org/10.1371/journal.pmed.1000218.
- França CT, He WQ, Gruszczyk J, Lim NTY, Lin E, Kiniboro B, et al. Plasmodium vivax Reticulocyte Binding
 Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children. *PLoS Negl*
- 584 Trop Dis 2016a;10:1–17. https://doi.org/10.1371/journal.pntd.0005014.

- França CT, Hostetler JB, Sharma S, White MT, Lin E, Kiniboro B, et al. An Antibody Screen of a Plasmodium
 vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection. *PLoS Negl Trop Dis* 2016b;10:1–15. https://doi.org/10.1371/journal.pntd.0004639.
- 588 Gnidehou S, Mitran CJ, Arango E, Banman S, Mena A, Medawar E, et al. Cross-species immune recognition 589 between plasmodium vivax duffy binding protein antibodies and the plasmodium falciparum surface antigen 590 VAR2CSA. *J Infect Dis* 2019;219:110–20. https://doi.org/10.1093/infdis/jiy467.
- Helb DA, Tetteh KKA, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, et al. Novel serologic biomarkers provide
 accurate estimates of recent *Plasmodium falciparum* exposure for individuals and communities. *Proc Natl Acad Sci* 2015;112:E4438–47. https://doi.org/10.1073/pnas.1501705112.
- Hester J, Chan ER, Menard D, Mercereau-Puijalon O, Barnwell J, Zimmerman PA, et al. De Novo Assembly of a
 Field Isolate Genome Reveals Novel Plasmodium vivax Erythrocyte Invasion Genes. *PLoS Negl Trop Dis* 2013;7.
 https://doi.org/10.1371/journal.pntd.0002569.
- van den Hoogen LL, Bareng P, Alves J, Reyes R, Macalinao M, Rodrigues JM, et al. Comparison of Commercial
 ELISA Kits to Confirm the Absence of Transmission in Malaria Elimination Settings. *Front Public Heal* 2020a;8:1–
 12. https://doi.org/10.3389/fpubh.2020.00480.
- van den Hoogen LL, Griffin JT, Cook J, Sepúlveda N, Corran P, Conway DJ, et al. Serology describes a profile
 of declining malaria transmission in Farafenni, The Gambia. *Malar J* 2015;14:416.
- 602 https://doi.org/10.1186/s12936-015-0939-1.
- van den Hoogen LL, Présumé J, Romilus I, Mondélus G, Elismé T, Sepúlveda N, et al. Quality control of
 multiplex antibody detection in samples from large-scale surveys: the example of malaria in Haiti. *Sci Rep* 2020b;10:1–10. https://doi.org/10.1038/s41598-020-57876-0.
- van den Hoogen LL, Stresman G, Présumé J, Romilus I, Mondélus G, Elismé T, et al. Selection of Antibody
 Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination. *Front Immunol* 2020c;11:1–12. https://doi.org/10.3389/fimmu.2020.00928.
- van den Hoogen LL, Walk J, Oulton T, Reuling IJ, Reiling L, Beeson JG, et al. Antibody Responses to Antigenic
 Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium
 falciparum Infections. *Front Microbiol* 2019;9:1–11. https://doi.org/10.3389/fmicb.2018.03300.
- Hubbard A, Munoz ID, Decker A, Holcomb JB, Schreiber MA, Bulger EM, et al. Time-dependent prediction and
 evaluation of variable importance using superlearning in high-dimensional clinical data. *J Trauma Acute Care Surg* 2013;75:1–12. https://doi.org/10.1097/TA.0b013e3182914553.
- Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, et al. Serological measures to assess the
 efficacy of malaria control programme on Ambae Island, Vanuatu. *Parasites and Vectors* 2017;10.
 https://doi.org/10.1186/s13071-017-2139-z.
- Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, et al. Serological markers to measure recent changes
 in malaria at population level in Cambodia. *Malar J* 2016;15:1–18. https://doi.org/10.1186/s12936-016-1576-z.
- King CL, Davies DH, Felgner P, Baum E, Jain A, Randall A, et al. Biosignatures of Exposure/Transmission and
 Immunity. *Am J Trop Med Hyg* 2015;93:16–27. https://doi.org/10.4269/ajtmh.15-0037.
- Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, et al. Analysis of antibody profiles in
 symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based
 serological assay (MAGPIX[™]). *Malar J* 2015;14. https://doi.org/10.1186/s12936-015-1043-2.
- Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, et al. Development and validation of serological markers for detecting recent Plasmodium vivax infection. *Nat Med* 2020;26:741–9. https://doi.org/10.1038/s41591-020-0841-4.
- malERA Refresh Consultative Panel. malERA: An updated research agenda for characterising the reservoir and
 measuring transmission in malaria elimination and eradication. *PLOS Med* 2017;14:e1002452.
 https://doi.org/10.1371/journal.pmed.1002452.
- Menard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole Genome Sequencing of Field
 Isolates Reveals a Common Duplication of the Duffy Binding Protein Gene in Malagasy Plasmodium vivax
 Strains. *PLoS Negl Trop Dis* 2013;7. https://doi.org/10.1371/journal.pntd.0002489.
- Mitran CJ, Yanow SK. The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design. *Front Immunol* 2020;11:1–14. https://doi.org/10.3389/fimmu.2020.00335.
- Muh F, Kim N, Nyunt MH, Firdaus ER, Han JH, Hoque MR, et al. Cross-species reactivity of antibodies against

- plasmodium vivax blood-stage antigens to plasmodium knowlesi. *PLoS Negl Trop Dis* 2020;14:1–21.
 https://doi.org/10.1371/journal.pntd.0008323.
- Niass O, Saint-Pierre P, Niang M, Diop F, Diouf B, Faye MM, et al. Modelling dynamic change of malaria
 transmission in holoendemic setting (Dielmo, Senegal) using longitudinal measures of antibody prevalence to
 Plasmodium falciparum crude schizonts extract. *Malar J* 2017;16:1–12. https://doi.org/10.1186/s12936-017 2052-0.
- Ntumngia FB, Schloegel J, Barnes SJ, Mchenry AM, Singh S, King CL, et al. Conserved and variant epitopes of
 Plasmodium vivax duffy binding protein as targets of inhibitory monoclonal antibodies. *Infect Immun* 2012;80:1203–8. https://doi.org/10.1128/IAI.05924-11.
- Ondigo BN, Park GS, Gose SO, Ho BM, Ochola LA, Ayodo GO, et al. Standardization and validation of a
 cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens. *Malar J* 2012;11:1–17. https://doi.org/10.1186/1475-2875-11-427.
- Perraut R, Richard V, Varela ML, Trape JF, Guillotte M, Tall A, et al. Comparative analysis of IgG responses to
 Plasmodium falciparum MSP1p19 and PF13-DBL1α1 using ELISA and a magnetic bead-based duplex assay
 (MAGPIX®-Luminex) in a Senegalese meso-endemic community. *Malar J* 2014;13.
- 652 https://doi.org/10.1186/1475-2875-13-410.
- Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies
 to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in
 coastal Kenya. *Vaccine* 2006;24:4233–46. https://doi.org/10.1016/j.vaccine.2005.06.030.
- Pothin E, Ferguson NM, Drakeley CJ, Ghani AC. Estimating malaria transmission intensity from Plasmodium
 falciparum serological data using antibody density models. *Malar J* 2016;15:79. https://doi.org/10.1186/s12936016-1121-0.
- Proietti C, Krause L, Trieu A, Dodoo D, Gyan B, Koram KA, et al. Immune signature against Plasmodium
 falciparum antigens predicts clinical immunity in distinct malaria endemic communities. *Mol Cell Proteomics* 2019:mcp.RA118.001256. https://doi.org/10.1074/mcp.RA118.001256.
- Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, et al. Antibodies to PfSEA-1 block parasite
 egress from RBCs and protect against malaria infection. *Science (80-)* 2014;344:871–7.
 https://doi.org/10.1126/science.1254417.
- Reyes RA, Fornace KM, Macalinao MLM, Boncayao BL, de la Fuente ES, Sabanal HM, et al. Enhanced health
 facility surveys to support malaria control and elimination across different transmission settings in the
 Philippines. *Am J Trop Med Hyg* 2021;104:968–78. https://doi.org/10.4269/ajtmh.20-0814.
- Rogier E, Nace D, Dimbu PR, Wakeman B, Pohl J, Beeson JG, et al. Framework for Characterizing Longitudinal
 Antibody Response in Children After Plasmodium falciparum Infection. *Front Immunol* 2021;12:1–11.
 https://doi.org/10.3389/fimmu.2021.617951.
- Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the
 identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine
 learning study. *The Lancet Microbe* 2020;5247:1–10. https://doi.org/10.1016/s2666-5247(20)30197-x.
- Rosas-Aguirre A, Speybroeck N, Llanos-Cuentas A, Rosanas-Urgell A, Carrasco-Escobar G, Rodriguez H, et al.
 Hotspots of malaria transmission in the Peruvian amazon: Rapid assessment through a parasitological and
 serological survey. *PLoS One* 2015;10. https://doi.org/10.1371/journal.pone.0137458.
- Sepúlveda N, Stresman G, White MT, Drakeley CJ. Current mathematical models for analyzing anti-malarial
 antibody data with an eye to malaria elimination and eradication. *J Immunol Res* 2015;2015.
 https://doi.org/10.1155/2015/738030.
- Spielmann T, Fergusen DJP, Beck H-P. etramps , a New Plasmodium falciparum Gene Family Coding for
 Developmentally Regulated and Highly Charged Membrane Proteins Located at the Parasite–Host Cell
 Interface. *Mol Biol Cell* 2003;14:1529–44. https://doi.org/10.1091/mbc.e02-04-0240.
- Ssewanyana I, Arinaitwe E, Nankabirwa JI, Yeka A, Sullivan R, Kamya MR, et al. Avidity of anti malarial
 antibodies inversely related to transmission intensity at three sites in Uganda. *Malar J* 2017:1–8.
 https://doi.org/10.1186/s12936-017-1721-3.
- Stanisic DI, Fowkes FJI, Koinari M, Javati S, Lin E, Kiniboro B, et al. Acquisition of antibodies against
 Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of
 infection, and magnitude of response. *Infect Immun* 2015;83. https://doi.org/10.1128/IAI.02398-14.
- Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum

- merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. *Infect Immun* 1995;63:4382–8. https://doi.org/10.1128/iai.63.11.4382-4388.1995.
- Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. *Clin Diagn Lab Immunol*
- glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. C
 1995;2:30–4. https://doi.org/10.1128/cdli.2.1.30-34.1995.
- 695 World Health Organization. World Malaria Report 2019. vol. WHO/HTM/GM. Geneva, Switzerland: 2019.
- World Health Organization. WHO malaria policy advisory committee meeting: meeting report, October 2017.Geneva, Switzerland: 2017.
- World Health Organization. Progress towards subnational elimination in the Philippines. Geneva PP Geneva:
 World Health Organization; 2014.
- World Health Organization, Global Malaria Programme. A Framework for Malaria Elimination. 2017.
 https://doi.org/Licence: CC BY-NC-SA 3.0 IGO.
- Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H, et al. Optimisation and standardisation of a
 multiplex immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission
 using sero-epidemiology. *Wellcome Open Res* 2019;4:26. https://doi.org/10.12688/wellcomeopenres.14950.1.
- 705 Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, et al. Sero-epidemiological evaluation of malaria
- transmission in The Gambia before and after mass drug administration. *BMC Med* 2020a;18:1–14.
 https://doi.org/10.1186/s12916-020-01785-6.
- Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, et al. Antibody responses to a suite of novel serological
 markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across
- seasons and transmission settings in The Gambia. *BMC Med* 2020b:2020.07.10.20067488.
- 711 https://doi.org/10.1101/2020.07.10.20067488.
- 712



Supplementary Figure 1. Antibody levels in response to the rest of the *P. falciparum* and *P. vivax* serological markers in the panel, by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons. Related to Fig. 1.

714

717

Model		Seropositivity cutoff value for antigens	AUC – validation data	AUC – study data	Positive in AUC – study data Pf+ samples (n=625)		ve in Positive in nples Palawan, 25) n=6572 (%)		Positive in Occidental Mindoro, n=1683 (%)		Positive in Bataan, n=877 (%)	
	FMM	129.552007	0.9075 (0.8866-0.9284)	0.6921 (0.6771-0.7072)	509	(85.5%)	3842	(58.5%)	599	(35.6%)	91	(10.4%)
FIAMAI	Negpop	146.705091	0.9115 (0.892-0.9311)	0.6948 (0.6795-0.71)	507	(85.2%)	3792	(57.7%)	582	(34.6%)	82	(9.4%)
	FMM	315.978321	0.9321 (0.9182-0.9459)	0.6849 (0.6696-0.7002)	503	(84.5%)	3872	(58.9%)	639	(38.0%)	85	(9.7%)
FINISE 119	Negpop	294.522036	0.9301 (0.9152-0.9449)	0.6821 (0.667-0.6973)	508	(85.4%)	3940	(60.0%)	658	(39.1%)	89	(10.1%)
EtrompE Ag1	FMM	343.006451	0.9075 (0.8918-0.9232)	0.7556 (0.7389-0.7722)	477	(80.2%)	2659	(40.5%)	267	(15.9%)	60	(6.8%)
Etramps.Ag i	Negpop	254.493948	0.9111 (0.8941-0.9281)	0.7397 (0.7235-0.7559)	489	(82.2%)	2963	(45.1%)	362	(21.5%)	87	(9.9%)
	FMM	402.149776	0.8848 (0.8663-0.9033)	0.7456 (0.7278-0.7633)	452	(76.0%)	2524	(38.4%)	203	(12.1%)	65	(7.4%)
GEAPTO	Negpop	267.001733	0.9037 (0.8849-0.9225)	0.7317 (0.7154-0.748)	487	(81.8%)	3067	(46.7%)	326	(19.4%)	126	(14.4%)
PfGLURP R2	FMM	346.692889	0.9206 (0.901-0.9401)	0.6849 (0.6701-0.6997)	516	(86.7%)	3817	(58.1%)	747	(44.4%)	147	(16.8%)
	Negpop	361.031502	0.9254 (0.9074-0.9435)	0.6855 (0.6706-0.7004)	512	(86.1%)	3810	(58.0%)	738	(43.9%)	143	(16.3%)
MSP2	FMM	137.354929	0.8558 (0.8325-0.879)	0.6849 (0.6665-0.7034)	437	(73.4%)	3093	(47.1%)	414	(24.6%)	76	(8.7%)
CH150/9	Negpop	141.708302	0.8541 (0.8307-0.8774)	0.4971 (0.4921-0.5022)	437	(73.4%)	3074	(46.8%)	406	(24.1%)	75	(8.6%)
	FMM	121.316261	0.9177 (0.9027-0.9326)	0.6762 (0.6598-0.6926)	484	(81.3%)	3673	(55.9%)	657	(39.0%)	126	(14.4%)
MSP2 Duz	Negpop	110.971531	0.9202 (0.9054-0.935)	0.6798 (0.6632-0.6965)	482	(81.0%)	3607	(54.9%)	615	(36.5%)	105	(12.0%)
	FMM	733.501223	0.8207 (0.7975-0.844)	0.6714 (0.6515-0.6912)	384	(64.5%)	2387	(36.3%)	470	(27.9%)	131	(14.9%)
FISEA	Negpop	867.158828	0.8121 (0.7918-0.8324)	0.6614 (0.6411-0.6816)	357	(60.0%)	2203	(33.5%)	409	(24.3%)	112	(12.8%)
Random Fores covariates (RF.	t: 4 covar4)	(Etramp5.Ag1, GEXP18, PfGLURP R2, PfMSP1 ₁₉)	0.9983 (0.996-1)	0.9591 (0.9497-0.9684)	552	(92.8%)	1081	(16.4%)	5	(0.3%)	1	(0.1%)
Random Fores covariates (RF.	t: 8 covar8)	All 8 Pf-specific antigens	0.9898 (0.998-1)	0.9682 (0.9605-0.9759)	555	(93.3%)	1065	(16.2%)	3	(0.2%)	0	(0.0%)
SL: 3 covariates (SL:3-covar)		(Etramp5.Ag1, GEXP18, PfGLURP R2)	0.918 (0.9067-0.9293)	0.879 (0.8658-0.8921)	265	(44.5%)	809	(12.3%)	0	(0.0%)	0	(0.0%)
SL: 4 covariates (SL:4-covar)		(Etramp5.Ag1, GEXP18, PfGLURP R2, PfMSP1 ₁₉)	0.9338 (0.9214-0.9462)	0.8967 (0.8867-0.9067)	297	(49.9%)	687	(10.5%)	0	(0.0%)	0	(0.0%)
SL: 8 covariate (SL:8-covar)	S	All 8 Pf-specific antigens	0.955 (0.9486-0.9614)	0.914 (0.9055-0.9226)	317	(53.3%)	828	(12.6%)	0	(0.0%)	0	(0.0%)
SL: 9 covariate (SL:9-covar)	es	All 8 Pf-specific antigens and age	0.9898 (0.9874-0.9921)	0.9197 (0.9093-0.9302)	423	(71.1%)	1245	(18.9%)	4	(0.2%)	0	(0.0%)

Supplementary Table 1. Seropositivity rates based on Pf-specific antigens and SuperLearner predictions for recent Pf exposure

*Abbreviations used: Pf: *P. falciparum;* FMM: Finite mixture model; Negpop: Negative population model; SL: Super Learner prediction model using different sets of covariates (including the 8 Pf antigens) for predicting recent and historical malaria exposure.

Model		Seropositivity cutoff value for antigens	AUC – validation data	AUC – study data	Positive in Pv+ samples (n=172)		Positive in Pv+ samples (n=172)		Pos Pa n=6	sitive in Iawan, 572 (%)	Po Oc M n=	sitive in cidental indoro, 1683 (%)	Po Bata	sitive in an, n=877 (%)
	FMM	149.776739	0.9185 (0.8934 - 0.9436)	0.6744 (0.6424 - 0.7064)	130	(75.6%)	2991	(45.5%)	650	(38.6%)	84	(9.6%)		
FVAIMAT	Negpop	172.486298	0.9164 (0.8895 - 0.9434)	0.6720 (0.6391 - 0.7049)	127	(73.8%)	3035	(46.2%)	626	(37.2%)	77	(8.8%)		
PvMSP1 ₁₉	FMM	395.678911	0.9429 (0.9229 - 0.9629)	0.7308 (0.6997 - 0.7618)	134	(77.9%)	2588	(39.4%)	430	(25.5%)	63	(7.2%)		
	Negpop	666.248684	0.9234 (0.8935 - 0.9533)	0.7049 (0.6692 - 0.7406)	114	(66.3%)	2135	(32.5%)	295	(17.5%)	38	(4.3%)		
PvDBP.RII	FMM	403.658933	0.8036 (0.7546 - 0.8527)	0.7065 (0.6697 - 0.7434)	105	(61.0%)	1699	(25.9%)	165	(9.8%)	50	(5.7%)		
	Negpop	285.09444	0.8143 (0.7668 - 0.8618)	0.7037 (0.6681 - 0.7392)	115	(66.9%)	2087	(31.8%)	221	(13.1%)	72	(8.2%)		
	FMM	777.354467	0.7367 (0.6865 - 0.7869)	0.6248 (0.5871 - 0.6625)	92	(53.5%)	1979	(30.1%)	416	(24.7%)	242	(27.6%)		
PVRBP.1a	Negpop	2986.35245	0.5343 (0.5006 - 0.5679)	0.5127 (0.4901 - 0.5352)	17	(9.9%)	507	(7.7%)	104	(6.2%)	61	(7.0%)		
DUDII	FMM	843.409764	0.7706 (0.7195 - 0.8218)	0.6302 (0.5935 - 0.6670)	67	(39.0%)	1079	(16.4%)	104	(6.2%)	38	(4.3%)		
PVRII	Negpop	377.466964	0.8007 (0.7530 - 0.8484)	0.6322 (0.5955 - 0.6688)	107	(62.2%)	2717	(41.3%)	489	(29.1%)	102	(11.6%)		
	FMM	147.668259	0.7735 (0.7247 - 0.8224)	0.6471 (0.6144 - 0.6799)	128	(74.4%)	3328	(50.6%)	719	(42.7%)	106	(12.1%)		
PVEBP	Negpop	661.785062	0.7133 (0.6616 - 0.7649)	0.6184 (0.5809 - 0.6559)	101	(58.7%)	2608	(39.7%)	566	(33.6%)	63	(7.2%)		
SL: 6 Pv antig	ens	All Py-specific	0.8857 (0.8429-0.9284)	0.6332 (0.5979-0.6686)	57	(33.1%)	603	(9.2%)	35	(2.1%)	2	(0.2%)		
RF: 6 Pv antig	ens	antigens as	1	0.6918 (0.6542-0.7293)	81	(47.1%)	802	(12.2%)	57	(3.4%)	5	(0.6%)		
GBM: 6 Pv antigens		covariates	0.9043 (0.8647-0.9439)	0.6462 (0.6095-0.6828)	67	(39.0%)	851	(12.9%)	80	(4.8%)	7	(0.8%)		

Supplementary Table 2. Seropositivity rates based on 6 Pv-specific antigens and SuperLearner predictions for recent Pv exposure

*Abbreviations used: Pv: P. vivax; FMM: Finite mixture model; Negpop: Negative population model; SL: Superlearner prediction model using different sets of covariates (including the 8 Pf antigens) for predicting recent and historical malaria exposure.

719

722 **Tables and figures**

723 **<u>Tables</u>**

- 724 **Table 1.** List of antigens in the multiplex bead-based assay panel
- 725 **Table 2.** Training and validation data used in the classification models
- 726 **Table 3.** Characteristics of study population by site
- 727 **Table 4.** Seroconversion and seroreversion rates from reverse catalytic models in each study site
- Supplementary Table 1. Seropositivity rates based on Pf-specific antigens and SuperLearner predictions
 for recent Pf exposure
- Supplementary Table 2. Seropositivity rates based on 6 Pv-specific antigens and SuperLearner
 predictions for recent Pv exposure

732 Figures

Figure 1. Map showing the study sites, with red areas as the focused municipalities within the provinces
 marked yellow.

Figure 2. Antibody responses to serological markers of *P. falciparum* and *P. vivax* correlate with malaria incidence

- A. Antibody levels (reported as log10 MFI) in response to *P. falciparum* cumulative and recent exposure markers PfAMA1, PfMSP1₁₉, and Etramp5.Ag1, and *P. vivax* serological markers PvAMA1, PvMSP1₁₉ and PvDBP.RII by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
- B. Spearman's correlation coefficients for age, malaria diagnosis (Mal+: Plasmodium-positive, Pf+: *P. falciparum*-positive, Pv+: *P. vivax*-positive), and antibody responses to the 14 antigens in the panel for Palawan samples (n=6572).

Figure 3. Serological markers exhibit species-specific association with current infection in varying levels

A-B) Comparison of antibody titers of Palawan samples (n=6572) for *Plasmodium*-positive (Pf: P. falciparum-positive, Pf/Pv: Pf and Pv mixed infection, Pv: P. vivax-positive) and negative (neg) samples by age group in each *P. falciparum*-specific (A) and *P.vivax*-specific antigen.

750 Figure 4. Analysis of serological markers through machine learning methods improves

- r51 classifications for recent *P. falciparum* and *P. vivax* exposure or current infection
- A-B. Seropositivity rates of sample population by site and age group based on cutoff values from finite mixture models (FMM) and negative population model (NegPop) for Pf and Pv antigens (detailed in Supplementary Tables 1 and 2). Hollow dots represent the FMM and Negpop seropositivity rates for the two reported recent exposure markers Etramp5.Ag1 and GEXP18 for Pf (A), and PvMSP1₁₉ and PvDBP.RII for Pv (B) panel. Lines with error bars represent median with 95% CI.
- 757 C-D. Receiver operating characteristic (ROC) curves for the antibody responses to single antigens for
 758 individual antigens, and for the SL models (shown in both as binary outcomes of seropositivity /
 759 prediction values).
- **E-F.** Variable importance of the 8 Pf-specific (E) and 6 Pv-specific (F) antigens based on the Random
 Forest model.
- G. Predicted rates of recent Pf exposure based on analysis of the continuous antibody responses of the
 8-antigen panel using Super Learner. Each hollow dot represents differences in the number of
 covariates used for the model (3, 4, 8, 9), as well as 2 showing rates from prediction values of the
 Random Forests (RF) component model (RF.covar4 and RF.covar8 in solid dots).
- H. Predicted rates of recent Pv exposure based on analysis of the continuous antibody responses of the
 6-antigen panel using Super Learner. Dots represent the positivity rates from the prediction

values of the SL model, and the individual predictions from the 2 most weighted base learners in 768 the resulting model - RF and GBM. RF predictions (RF.covar6) are shown as solid dots. 769 (SL: Super Learner, RF: random Forest, covar#: number of covariates included in the model, FMM: finite 770 mixture models; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 with significance assessed by one-way 771 ANOVA followed by Tukey's multiple comparison) 772

Figure 5. Seroconversion curves based on reverse catalytic models using AMA1 and MSP1₁₉ 773 antibody responses provide accurate estimates of historical exposure.

- 774
- Age-specific seroprevalence was based on finite mixture models and Random Forest models (using both 775
- antigens: RF 2-covar models) for each species. Solid lines represent the fit of the reversible catalytic 776 models, dashed lines represent 95% confidence intervals, and dots represent the observed proportions of 777 seropositives per age divided into 10% centiles. For models assuming a change point in transmission, only 778 the recent seroconversion rates and change point estimates (in years) are shown, while the historical 779 seroconversion rates and seroreversion rates are detailed in Table 4. 780
- Figure 6. Cumulative exposure markers confirm historical P. falciparum and P. vivax exposure, and 781 heterogeneity of transmission in the 3 sites 782
- Plot of Super Learner prediction values for Pf historical exposure by site and age, using the model 783 Α. with 8 Pf-specific serological markers as covariates. Red dotted line represents positivity cutoff at 0.5. 784
- Variable importance based on the Random Forest model of the 8 Pf-specific antigens and 6 Pv-Β. 785 specific antigens in predicting historical exposure for each species. 786
- С. Distribution of antibody responses to PfAMA1 by site and age of individuals (n=9132). Red dashed 787 line represents the seropositivity cutoff value from the FMM model. 788
- D-E. Summary graphs per age category per site of SL-predicted Pf historical exposure (D) and PfAMA1, 789 PfMSP1 seropositivity rates graphed with estimated historical exposure rates using the Random 790 Forest model with PfAMA1, PfMSP1₁₉ as covariates (E). 791
- 792 F. Summary graph of PvAMA1, PvMSP1 seropositivity rates with estimated historical exposure rates using the Random Forest model with PvAMA1, PvMSP1₁₉ as covariates seropositivity per age 793 category per site 794
- 795 Supplementary Figure 1. Antibody levels in response to the rest of the *P. falciparum* and *P. vivax* serological markers in the panel, by study site and age group. Statistical difference of overall antibody 796 responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon 797 test for pairwise comparisons. Related to Fig. 1. 798
- Supplementary Figure 2. Antibody responses of malaria-negative and malaria-positive populations 799 (presented as density plots of log10 net MFI values) to the Pf and Pv serological markers in the panel (Pf 800 and Pv diagnosed by microscopy, RDT and/or PCR. Related to Fig. 1. 801

Supplementary Figure 3. Performances of the individual base learners in the Super Learner 802 ensemble. 803

- A-B) Plots of the assigned weights to each learner included in the Super Learner models for predicting P. 804 falciparum (A) and P. vivax recent exposure (B), obtained after 20-fold nested cross-validation of the 805 Pf SL-covar8 and Pv SL-covar6 models. 806
- C-D) Receiver operating characteristic (ROC) curves for detecting current Pf (C) and Pv (D) infections in 807 the test dataset (n=9132) using the 8 Pf and 6 Pv antigens as covariates, respectively. (SL.final: final 808 Super Learner model, RF: random Forest, RF.ranger: RF from ranger package, kNN: k-Nearest 809
- Neighbor, GBM: generalized boosted models (implementation for BRT: boosted regression trees), 810
- SVM:Support Vector Machine, and GLM: Generalized linear models; variation of algorithms with 811
- "corP" denotes a feature selection that screens for univariate correlation) 812
- 813